APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 170 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,381,776 | +102.3% | 194,053 | +384.5% | 0.04% | +94.7% |
| Q2 2023 | $3,648,828 | -82.6% | 40,053 | -87.4% | 0.02% | -83.6% |
| Q1 2023 | $20,945,796 | -10.1% | 317,553 | -29.5% | 0.12% | -16.5% |
| Q4 2022 | $23,290,184 | -28.7% | 450,400 | -5.8% | 0.14% | -23.2% |
| Q3 2022 | $32,647,000 | -66.7% | 478,000 | -69.2% | 0.18% | -54.8% |
| Q2 2021 | $97,960,000 | +5.0% | 1,550,000 | -28.7% | 0.40% | -13.8% |
| Q1 2021 | $93,329,000 | -28.3% | 2,175,000 | -4.4% | 0.46% | -40.7% |
| Q4 2020 | $130,130,000 | +89.6% | 2,275,000 | 0.0% | 0.78% | +64.8% |
| Q3 2020 | $68,637,000 | -6.6% | 2,275,000 | +1.1% | 0.48% | -19.2% |
| Q2 2020 | $73,485,000 | +37.2% | 2,250,000 | +12.5% | 0.59% | +27.8% |
| Q1 2020 | $53,580,000 | +250.0% | 2,000,000 | +300.0% | 0.46% | +346.6% |
| Q4 2019 | $15,310,000 | – | 500,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |